Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.

ABSTRACT: Motivation:Proteomics profiling is increasingly being used for molecular stratification of cancer patients and cell-line panels. However, systematic assessment of the predictive power of large-scale proteomic technologies across various drug classes and cancer types is currently lacking. To that end, we carried out the first pan-cancer, multi-omics comparative analysis of the relative performance of two proteomic technologies, targeted reverse phase protein array (RPPA) and global mass spectrometry (MS), in terms of their accuracy for predicting the sensitivity of cancer cells to both cytotoxic chemotherapeutics and molecularly targeted anticancer compounds. Results:Our results in two cell-line panels demonstrate how MS profiling improves drug response predictions beyond that of the RPPA o

SUBMITTER: Ali M 

PROVIDER: S-EPMC5905617 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature